Abstract
Background/Aim: Currently, olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has been approved as maintenance therapy for patients with germli......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
